Janney Montgomery Scott LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 5.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,724 shares of the medical device company’s stock after selling 636 shares during the period. Janney Montgomery Scott LLC’s holdings in DexCom were worth $1,750,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Gradient Investments LLC bought a new stake in shares of DexCom in the 2nd quarter worth approximately $25,000. Virtus ETF Advisers LLC bought a new stake in shares of DexCom in the 2nd quarter worth approximately $29,000. Steward Partners Investment Advisory LLC bought a new stake in shares of DexCom in the 2nd quarter worth approximately $31,000. CSat Investment Advisory L.P. bought a new stake in shares of DexCom in the 2nd quarter worth approximately $31,000. Finally, Wealthcare Advisory Partners LLC bought a new stake in shares of DexCom in the 2nd quarter worth approximately $37,000. 96.19% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ DXCM opened at $194.70 on Friday. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56. DexCom, Inc. has a twelve month low of $105.05 and a twelve month high of $200.80. The firm has a market capitalization of $14.00 billion, a PE ratio of 649.00 and a beta of 0.64. The stock’s 50 day moving average is $154.75 and its 200 day moving average is $145.88.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The company had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. During the same period in the previous year, the company posted $0.17 earnings per share. The firm’s revenue was up 48.6% on a year-over-year basis. On average, research analysts anticipate that DexCom, Inc. will post 0.94 earnings per share for the current year.

In other DexCom news, Director Nicholas Augustinos sold 1,208 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $145.49, for a total value of $175,751.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $157.50, for a total value of $1,575,000.00. The disclosure for this sale can be found here. Insiders sold 104,014 shares of company stock worth $16,183,576 over the last three months. Corporate insiders own 1.80% of the company’s stock.

DXCM has been the topic of a number of recent analyst reports. Oppenheimer lifted their price objective on DexCom from $180.00 to $205.00 in a research report on Thursday. Stifel Nicolaus initiated coverage on DexCom in a research report on Tuesday, October 22nd. They issued a “buy” rating and a $190.00 price objective on the stock. ValuEngine lowered DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. BMO Capital Markets lifted their price target on DexCom from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Finally, Bank of America lifted their price target on DexCom from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $184.33.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What is a price target?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.